Longeveron Inc.
$1.04
▼
-4.46%
2026-04-21 07:53:02
longeveron.com
NCM: LGVN
Explore Longeveron Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$25.59 M
Current Price
$1.04
52W High / Low
$1.83 / $0.47
Stock P/E
—
Book Value
$0.25
Dividend Yield
—
ROCE
-377.18%
ROE
-1.65%
Face Value
—
EPS
$-1.29
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
38
Beta
-0.19
Debt / Equity
14.52
Current Ratio
1.33
Quick Ratio
1.33
Forward P/E
-0.76
Price / Sales
28.33
Enterprise Value
$23.15 M
EV / EBITDA
-1.05
EV / Revenue
19.31
Rating
None
Target Price
$5.48
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Calidi Biotherapeutics, Inc. | $0.25 | — | $3 M | — | -410.2% | -7.01% | $19.2 / $0.21 | $0.51 |
| 2. | Recursion Pharmaceuticals, Inc. | $3.69 | — | $1.95 B | — | -48.86% | -59.54% | $7.18 / $2.8 | $2.14 |
| 3. | Lineage Cell Therapeutics, Inc. | $1.65 | — | $410.99 M | — | -21.52% | -1.05% | $2.09 / $0.4 | $0.18 |
| 4. | Biomea Fusion, Inc. | $2.05 | — | $159.78 M | — | -171.28% | -1.52% | $3.08 / $0.87 | $0.41 |
| 5. | REGENXBIO Inc. | $9.47 | — | $488.82 M | — | -48.13% | -1.07% | $16.19 / $5.85 | $2.02 |
| 6. | HCW Biologics Inc. | $0.41 | — | $2.94 M | — | -4764.31% | -897.37% | $17.8 / $0.25 | $-0.8 |
| 7. | Nektar Therapeutics | $100.35 | — | $2.87 B | — | -57.64% | -2.18% | $109 / $7.99 | $4.41 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.36 M | 0.14 M | 0.32 M | 0.38 M | 0.6 M | — |
| Operating Profit | -5.4 M | -7.31 M | -5.4 M | -5.18 M | -4.28 M | — |
| Net Profit | -5.44 M | -7.22 M | -5.03 M | -5.01 M | -4.08 M | — |
| EPS in Rs | -0.2 | -0.26 | -0.18 | -0.18 | -0.15 | -0.34 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.2 M | 2.39 M | 0.71 M | 1.22 M |
| Operating Profit | -23.29 M | -16.52 M | -21.03 M | -18.04 M |
| Net Profit | -22.7 M | -15.97 M | -21.41 M | -18.84 M |
| EPS in Rs | -0.82 | -0.57 | -0.77 | -0.68 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 10.26 M | 25.56 M | 12.08 M | 27.41 M |
| Total Liabilities | 4.59 M | 3.67 M | 5.34 M | 6.91 M |
| Equity | 5.67 M | 21.89 M | 6.74 M | 20.5 M |
| Current Assets | 5.45 M | 19.62 M | 5.85 M | 20.28 M |
| Current Liabilities | 4.09 M | 2.58 M | 3.89 M | 4.87 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -18.64 M | -13.87 M | -19 M | -13.97 M |
| Investing CF | -0.59 M | -0.64 M | 8.19 M | -0.68 M |
| Financing CF | 4.67 M | 28.79 M | 5.26 M | -0.51 M |
| Free CF | -19.24 M | -14.86 M | -19.7 M | -14.82 M |
| Capex | -0.59 M | -0.99 M | -0.69 M | -0.86 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 237.38% | -41.98% | — | — |
| Earnings Growth % | 25.41% | -13.69% | — | — |
| Profit Margin % | -667.77% | -3020.17% | -1541.33% | — |
| Operating Margin % | -690.72% | -2966.01% | -1476.51% | — |
| Gross Margin % | 78.76% | 31.17% | 40.67% | — |
| EBITDA Margin % | -650.67% | -2832.58% | -1403.44% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-03-27 | 1:0.1 |